Abstract
The report covers forecast and analysis for the erectile dysfunction drugs market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the erectile dysfunction drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the erectile dysfunction drugs market on a global level.
In order to give the users of this report a comprehensive view of the erectile dysfunction drugs market, we have included the competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein drug, mode of administration, distribution channel, and regional segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on the global and regional basis.
The study provides a decisive view of the erectile dysfunction drugs market by segmenting the market based on drug, mode of administration, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa with its further bifurcation into major countries.
Some of the leading players in erectile dysfunction drugs market include Apricus Biosciences, Bayer AG, Cristália, Eli Lilly and Company, Inc., Pfizer, Inc., Dong-A-Pharmaceutical Co., Ltd., S.K. Chemicals Co., Ltd., Vivus, Inc., Teva Pharmaceutical Industries Ltd. and Meda Pharmaceuticals, Inc.
This report segments the global erectile dysfunction drugs market as follows:
Global Erectile Dysfunction Drugs Market: Drug Segment Analysis
Sildenafil Citrate (Viagra)
Vardenafil (Levitra/ Staxyn)
Tadalafil (Cialis)
Udenafil (Zydena)
Lodenafil Carbonate (Helleva)
Stendra/ Spedra (Avanafil)
Mirodenafil (Mvix)
Others
Global Erectile Dysfunction Drugs Market: Mode of Administration Segment Analysis
Oral Medications
Topical Medications
Injections
Others
Global Erectile Dysfunction Drugs Market: Distribution Channel Segment Analysis
Hospital Pharmacies
Retail Pharmacies
Online Sales
Global Erectile Dysfunction Drugs Market: Regional Segment Analysis
North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
Middle East and Africa